Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG033
- Development stage
- Preclinical
- Lead developer
- Biocytogen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BCG033 is a first-in-class bispecific antibody-drug conjugate (ADC) developed by Biocytogen Pharmaceuticals that simultaneously targets two tumor-associated antigens: protein tyrosine kinase 7 (PTK7) and trophoblast cell-surface antigen 2 (TROP2). Generated using the proprietary RenLite® platform, BCG033 features a fully human bispecific antibody with a common light chain, conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via the proprietary BLD1102 linker. This dual-targeting approach is designed to enhance therapeutic efficacy and selectivity while reducing off-target effects compared to conventional single-target ADCs. Preclinical studies have demonstrated significant anti-tumor activity in models of triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), gastric cancer, and colorectal cancer. The drug is currently in the preclinical stage of development.
02
Targets
PTK7 (Protein tyrosine kinase 7)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on BCG033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG033.